Nacom (Levodopa, Carbidopa Monohydrate)

Levodopa/Carbidopa, the active ingredient in Nacom, is a dopamine precursor presented as an oral tablet for oral use. It is indicated for the management of Parkinson's disease in adults, helping to replenish depleted central dopamine levels.\n\nGNH India supplies Nacom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa acts on the dopaminergic pathway to treat Parkinsonian disorders.\n\nParkinson's disease: improves motor function, reduces bradykinesia and rigidity.\nParkinsonian syndrome: alleviates tremor and stiffness associated with secondary parkinsonism.\nLevodopa‑responsive dystonia: reduces abnormal muscle tone and involuntary movements.

Levodopa/Carbidopa may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Nausea or vomiting\n- Dizziness or orthostatic hypotension\n- Headache\n- Insomnia or vivid dreams\n- Dyskinesia (involuntary movements)\n\nSerious or Rare Side Effects:\n- Neuroleptic malignant‑like syndrome\n- Severe orthostatic hypotension leading to fainting\n- Hallucinations or psychosis\n- Cardiac arrhythmias\n- Severe depression or suicidal thoughts

Use of levodopa/carbidopa requires careful monitoring and patient education.\n\nDose titration: start low and increase gradually to balance efficacy and side effects.\nBlood pressure monitoring: watch for orthostatic hypotension, especially after the first dose.\nRenal and hepatic function: assess before initiation and periodically during therapy.\nAvoid abrupt discontinuation: sudden stop may precipitate severe withdrawal reactions.\nPregnancy and lactation: prescribe only if benefits outweigh potential risks.\nStore at ambient temperature: keep in original packaging, protect from moisture and light.

Levodopa/carbidopa interacts with several drug classes that can alter its efficacy or safety.\n\nMajor Interactions (Avoid):\n- Non‑selective MAO inhibitors: risk of hypertensive crisis.\n- Anticholinergic agents: may mask motor symptom changes.\n- Iron or calcium supplements: reduce levodopa absorption.\n- High‑protein meals: decrease bioavailability of levodopa.\n\nModerate Interactions (Monitor Closely):\n- SSRIs or SNRIs: potential for serotonin syndrome.\n- Antihypertensive drugs: additive hypotensive effect.\n- Amantadine: may increase dyskinesia risk.